Baxter International Inc. (NYSE: BAX) Stock Competitors & Peer Comparison
See BAX's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BAX and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BAX | $22.40 | +3.37% | 11.6B | 10.77 | $2.08 | +0.89% |
| BDX | $156.36 | +2.22% | 56.6B | 11.62 | $13.45 | +2.39% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.39% |
| MDLN | $38.75 | +2.98% | 32.8B | 45.06 | $0.86 | N/A |
| WST | $328.20 | -7.67% | 23.2B | 41.19 | $7.97 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $70.31 | +0.11% | 13.7B | 15.42 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.39% |
| ATR | $132.36 | +2.61% | 8.4B | 23.13 | $5.72 | +1.43% |
| AVTR | $11.44 | +0.79% | 7.8B | 13.46 | $0.85 | N/A |
Stock Comparison
Becton, Dickinson and Company (NYSE: BDX)
BAX vs BDX Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, BDX has a market cap of 56.6B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while BDX trades at $156.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas BDX's P/E ratio is 11.62. In terms of profitability, BAX's ROE is -0.16%, compared to BDX's ROE of +0.05%. Regarding short-term risk, BAX is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for BAX.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
BAX vs BDXA Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas BDXA's P/E ratio is 45.70. In terms of profitability, BAX's ROE is -0.16%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, BAX is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for BAX.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
BAX vs MDLN Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, MDLN has a market cap of 32.8B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while MDLN trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas MDLN's P/E ratio is 45.06. In terms of profitability, BAX's ROE is -0.16%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, BAX is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for BAX.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
BAX vs WST Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, WST has a market cap of 23.2B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while WST trades at $328.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas WST's P/E ratio is 41.19. In terms of profitability, BAX's ROE is -0.16%, compared to WST's ROE of +0.19%. Regarding short-term risk, BAX is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for BAX.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
BAX vs HOLX Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas HOLX's P/E ratio is 31.54. In terms of profitability, BAX's ROE is -0.16%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, BAX is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for BAX.Check HOLX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
BAX vs COO Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, COO has a market cap of 13.7B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while COO trades at $70.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas COO's P/E ratio is 15.42. In terms of profitability, BAX's ROE is -0.16%, compared to COO's ROE of +0.03%. Regarding short-term risk, BAX is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for BAX.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
BAX vs BDXB Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas BDXB's P/E ratio is 7.60. In terms of profitability, BAX's ROE is -0.16%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, BAX is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for BAX.Check BDXB's competition here
AptarGroup, Inc. (NYSE: ATR)
BAX vs ATR Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while ATR trades at $132.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas ATR's P/E ratio is 23.13. In terms of profitability, BAX's ROE is -0.16%, compared to ATR's ROE of +0.14%. Regarding short-term risk, BAX is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for BAX.Check ATR's competition here
Avantor, Inc. (NYSE: AVTR)
BAX vs AVTR Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, AVTR has a market cap of 7.8B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while AVTR trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas AVTR's P/E ratio is 13.46. In terms of profitability, BAX's ROE is -0.16%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, BAX is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for BAX.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
BAX vs RGEN Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, RGEN has a market cap of 7.4B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while RGEN trades at $131.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas RGEN's P/E ratio is 73.31. In terms of profitability, BAX's ROE is -0.16%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, BAX is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for BAX.Check RGEN's competition here
Teleflex Incorporated (NYSE: TFX)
BAX vs TFX Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while TFX trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas TFX's P/E ratio is 12.32. In terms of profitability, BAX's ROE is -0.16%, compared to TFX's ROE of -0.28%. Regarding short-term risk, BAX is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for BAX.Check TFX's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
BAX vs BLCO Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while BLCO trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas BLCO's P/E ratio is 24.88. In terms of profitability, BAX's ROE is -0.16%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, BAX is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for BAX.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
BAX vs STVN Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, STVN has a market cap of 5.4B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while STVN trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas STVN's P/E ratio is 31.81. In terms of profitability, BAX's ROE is -0.16%, compared to STVN's ROE of +0.10%. Regarding short-term risk, BAX is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for BAX.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
BAX vs MMSI Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, MMSI has a market cap of 4.4B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while MMSI trades at $74.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas MMSI's P/E ratio is 19.01. In terms of profitability, BAX's ROE is -0.16%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, BAX is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for BAX.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
BAX vs ICUI Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while ICUI trades at $157.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas ICUI's P/E ratio is 19.66. In terms of profitability, BAX's ROE is -0.16%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, BAX is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for BAX.Check ICUI's competition here
Haemonetics Corporation (NYSE: HAE)
BAX vs HAE Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while HAE trades at $78.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas HAE's P/E ratio is 15.86. In terms of profitability, BAX's ROE is -0.16%, compared to HAE's ROE of +0.11%. Regarding short-term risk, BAX is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for BAX.Check HAE's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
BAX vs XRAY Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, XRAY has a market cap of 2.6B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while XRAY trades at $12.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas XRAY's P/E ratio is 9.04. In terms of profitability, BAX's ROE is -0.16%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, BAX is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for BAX.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
BAX vs LMAT Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while LMAT trades at $95.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas LMAT's P/E ratio is 37.05. In terms of profitability, BAX's ROE is -0.16%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, BAX is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for BAX.Check LMAT's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
BAX vs PLSE Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, PLSE has a market cap of 2.1B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while PLSE trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas PLSE's P/E ratio is -27.48. In terms of profitability, BAX's ROE is -0.16%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, BAX is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for BAX.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
BAX vs ATRC Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, ATRC has a market cap of 1.8B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while ATRC trades at $35.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas ATRC's P/E ratio is 1088.20. In terms of profitability, BAX's ROE is -0.16%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, BAX is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for BAX.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
BAX vs BLFS Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, BLFS has a market cap of 1.5B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while BLFS trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas BLFS's P/E ratio is -141.85. In terms of profitability, BAX's ROE is -0.16%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, BAX is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for BAX.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
BAX vs AZTA Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while AZTA trades at $27.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas AZTA's P/E ratio is 60.82. In terms of profitability, BAX's ROE is -0.16%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, BAX is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for BAX.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
BAX vs KMTS Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while KMTS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas KMTS's P/E ratio is -8.92. In terms of profitability, BAX's ROE is -0.16%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, BAX is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for BAX.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
BAX vs STAA Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while STAA trades at $23.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas STAA's P/E ratio is 41.02. In terms of profitability, BAX's ROE is -0.16%, compared to STAA's ROE of -0.06%. Regarding short-term risk, BAX is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for BAX.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
BAX vs QDEL Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, QDEL has a market cap of 1.1B. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while QDEL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas QDEL's P/E ratio is 11.98. In terms of profitability, BAX's ROE is -0.16%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, BAX is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for BAX.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
BAX vs ATRI Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas ATRI's P/E ratio is 64.50. In terms of profitability, BAX's ROE is -0.16%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, BAX is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for BAX.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
BAX vs ANGO Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, ANGO has a market cap of 561.7M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while ANGO trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas ANGO's P/E ratio is -34.85. In terms of profitability, BAX's ROE is -0.16%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, BAX is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for BAX.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
BAX vs NNNN Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, NNNN has a market cap of 441.5M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while NNNN trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas NNNN's P/E ratio is 145.38. In terms of profitability, BAX's ROE is -0.16%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, BAX is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for BAX.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
BAX vs OSUR Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, OSUR has a market cap of 273.3M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas OSUR's P/E ratio is -4.78. In terms of profitability, BAX's ROE is -0.16%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, BAX is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for BAX.Check OSUR's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
BAX vs SMTI Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, SMTI has a market cap of 234.2M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while SMTI trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas SMTI's P/E ratio is -426.00. In terms of profitability, BAX's ROE is -0.16%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, BAX is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for BAX.Check SMTI's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
BAX vs UTMD Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, UTMD has a market cap of 213.8M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while UTMD trades at $67.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas UTMD's P/E ratio is 19.86. In terms of profitability, BAX's ROE is -0.16%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, BAX is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for BAX.Check UTMD's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
BAX vs INFU Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, INFU has a market cap of 183.9M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while INFU trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas INFU's P/E ratio is 23.97. In terms of profitability, BAX's ROE is -0.16%, compared to INFU's ROE of +0.14%. Regarding short-term risk, BAX is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for BAX.Check INFU's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
BAX vs KRMD Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while KRMD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas KRMD's P/E ratio is -95.75. In terms of profitability, BAX's ROE is -0.16%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, BAX is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for BAX.Check KRMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
BAX vs PDEX Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, PDEX has a market cap of 175.4M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while PDEX trades at $54.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas PDEX's P/E ratio is 19.34. In terms of profitability, BAX's ROE is -0.16%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, BAX is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for BAX.Check PDEX's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
BAX vs MBOT Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, MBOT has a market cap of 77.9M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while MBOT trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas MBOT's P/E ratio is -6.58. In terms of profitability, BAX's ROE is -0.16%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, BAX is less volatile compared to MBOT. This indicates lower risk in terms of short-term price fluctuations for BAX.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
BAX vs AKYA Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas AKYA's P/E ratio is -1.34. In terms of profitability, BAX's ROE is -0.16%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, BAX is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for BAX.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
BAX vs STSS Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, STSS has a market cap of 58.4M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while STSS trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas STSS's P/E ratio is -0.02. In terms of profitability, BAX's ROE is -0.16%, compared to STSS's ROE of -1.66%. Regarding short-term risk, BAX is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for BAX.Check STSS's competition here
Daxor Corporation (NASDAQ: DXR)
BAX vs DXR Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, DXR has a market cap of 52.7M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while DXR trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas DXR's P/E ratio is 27.33. In terms of profitability, BAX's ROE is -0.16%, compared to DXR's ROE of +0.22%. Regarding short-term risk, BAX is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for BAX.Check DXR's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
BAX vs OMIC Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas OMIC's P/E ratio is -0.58. In terms of profitability, BAX's ROE is -0.16%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, BAX is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for BAX.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
BAX vs IGAP Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas IGAP's P/E ratio is -10.52. In terms of profitability, BAX's ROE is -0.16%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, BAX is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for BAX.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
BAX vs NEPH Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, NEPH has a market cap of 38.6M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while NEPH trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas NEPH's P/E ratio is 50.86. In terms of profitability, BAX's ROE is -0.16%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, BAX is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for BAX.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
BAX vs MLSS Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, MLSS has a market cap of 34.5M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas MLSS's P/E ratio is -6.50. In terms of profitability, BAX's ROE is -0.16%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, BAX is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for BAX.Check MLSS's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
BAX vs POCI Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, POCI has a market cap of 33.8M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while POCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas POCI's P/E ratio is -6.07. In terms of profitability, BAX's ROE is -0.16%, compared to POCI's ROE of -0.37%. Regarding short-term risk, BAX is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for BAX.Check POCI's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
BAX vs SDC Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas SDC's P/E ratio is -0.03. In terms of profitability, BAX's ROE is -0.16%, compared to SDC's ROE of -1.96%. Regarding short-term risk, BAX is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for BAX.Check SDC's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
BAX vs HBIO Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, HBIO has a market cap of 27.3M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while HBIO trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas HBIO's P/E ratio is -16.81. In terms of profitability, BAX's ROE is -0.16%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, BAX is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for BAX.Check HBIO's competition here
Invacare Corporation (NYSE: IVC)
BAX vs IVC Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas IVC's P/E ratio is -0.79. In terms of profitability, BAX's ROE is -0.16%, compared to IVC's ROE of -0.46%. Regarding short-term risk, BAX is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for BAX.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
BAX vs RVP Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas RVP's P/E ratio is -2.06. In terms of profitability, BAX's ROE is -0.16%, compared to RVP's ROE of -0.08%. Regarding short-term risk, BAX is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for BAX.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
BAX vs ZJYL Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, ZJYL has a market cap of 16M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while ZJYL trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas ZJYL's P/E ratio is 12.75. In terms of profitability, BAX's ROE is -0.16%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, BAX is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for BAX.Check ZJYL's competition here
Femasys Inc. (NASDAQ: FEMY)
BAX vs FEMY Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, FEMY has a market cap of 11.2M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while FEMY trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas FEMY's P/E ratio is -10.25. In terms of profitability, BAX's ROE is -0.16%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, BAX is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for BAX.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
BAX vs RGNT Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, RGNT has a market cap of 7.8M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while RGNT trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas RGNT's P/E ratio is -0.08. In terms of profitability, BAX's ROE is -0.16%, compared to RGNT's ROE of N/A. Regarding short-term risk, BAX is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for BAX.Check RGNT's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
BAX vs NSTG Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas NSTG's P/E ratio is -0.03. In terms of profitability, BAX's ROE is -0.16%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, BAX is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for BAX.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
BAX vs NXGL Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, NXGL has a market cap of 4M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while NXGL trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas NXGL's P/E ratio is -1.13. In terms of profitability, BAX's ROE is -0.16%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, BAX is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for BAX.Check NXGL's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
BAX vs POAI Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas POAI's P/E ratio is -0.03. In terms of profitability, BAX's ROE is -0.16%, compared to POAI's ROE of -107.05%. Regarding short-term risk, BAX is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for BAX.Check POAI's competition here
Lucyd, Inc (NASDAQ: LUCY)
BAX vs LUCY Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, LUCY has a market cap of 2.6M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while LUCY trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas LUCY's P/E ratio is -0.39. In terms of profitability, BAX's ROE is -0.16%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, BAX is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for BAX.Check LUCY's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
BAX vs MHUA Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas MHUA's P/E ratio is 0.25. In terms of profitability, BAX's ROE is -0.16%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, BAX is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for BAX.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
BAX vs NXGLW Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, NXGLW has a market cap of 1.8M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, BAX's ROE is -0.16%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, BAX is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for BAX.Check NXGLW's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
BAX vs GMVD Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas GMVD's P/E ratio is -0.01. In terms of profitability, BAX's ROE is -0.16%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, BAX is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for BAX.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
BAX vs GMVDW Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas GMVDW's P/E ratio is N/A. In terms of profitability, BAX's ROE is -0.16%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, BAX is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for BAX.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
BAX vs AVGR Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas AVGR's P/E ratio is -0.05. In terms of profitability, BAX's ROE is -0.16%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, BAX is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for BAX.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
BAX vs LUCYW Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas LUCYW's P/E ratio is -0.00. In terms of profitability, BAX's ROE is -0.16%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, BAX is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for BAX.Check LUCYW's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
BAX vs GCTK Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, GCTK has a market cap of 165.2K. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while GCTK trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas GCTK's P/E ratio is -0.01. In terms of profitability, BAX's ROE is -0.16%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, BAX is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for BAX.Check GCTK's competition here
Apria, Inc. (NASDAQ: APR)
BAX vs APR Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, APR has a market cap of 0. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas APR's P/E ratio is 22.59. In terms of profitability, BAX's ROE is -0.16%, compared to APR's ROE of +9.81%. Regarding short-term risk, BAX is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for BAX.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
BAX vs IIN Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, IIN has a market cap of 0. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas IIN's P/E ratio is 226.45. In terms of profitability, BAX's ROE is -0.16%, compared to IIN's ROE of -0.00%. Regarding short-term risk, BAX is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for BAX.Check IIN's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
BAX vs HRC Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, HRC has a market cap of 0. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas HRC's P/E ratio is 41.92. In terms of profitability, BAX's ROE is -0.16%, compared to HRC's ROE of +0.14%. Regarding short-term risk, BAX is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for BAX.Check HRC's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
BAX vs ATRS Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas ATRS's P/E ratio is 14.95. In terms of profitability, BAX's ROE is -0.16%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, BAX is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for BAX.Check ATRS's competition here
Invuity, Inc. (NASDAQ: IVTY)
BAX vs IVTY Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas IVTY's P/E ratio is -3.80. In terms of profitability, BAX's ROE is -0.16%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, BAX is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for BAX.Check IVTY's competition here
Analogic Corporation (NASDAQ: ALOG)
BAX vs ALOG Comparison July 2026
Baxter International Inc. (NYSE: BAX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 11.6B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, BAX is priced at $22.40 on the NYSE, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of 10.77, whereas ALOG's P/E ratio is 40.93. In terms of profitability, BAX's ROE is -0.16%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, BAX is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for BAX.Check ALOG's competition here